The degree of hepatic steatosis associates with impaired cardiac and autonomic function

[Display omitted] •Patients with elevated liver fat and poor metabolic control have impaired cardiac and autonomic function.•Liver fat, metabolic dysfunction, inflammation and fibrosis staging correlate with cardiac and autonomic dysfunction.•Elevated alcohol intake enhanced the impact of liver fat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of hepatology 2019-06, Vol.70 (6), p.1203-1213
Hauptverfasser: Houghton, David, Zalewski, Paweł, Hallsworth, Kate, Cassidy, Sophie, Thoma, Christian, Avery, Leah, Slomko, Joanna, Hardy, Timothy, Burt, Alastair D., Tiniakos, Dina, Hollingsworth, Kieren G., Taylor, Roy, Day, Christopher P., Masson, Steven, McPherson, Stuart, Anstee, Quentin M., Newton, Julia L., Trenell, Michael I.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[Display omitted] •Patients with elevated liver fat and poor metabolic control have impaired cardiac and autonomic function.•Liver fat, metabolic dysfunction, inflammation and fibrosis staging correlate with cardiac and autonomic dysfunction.•Elevated alcohol intake enhanced the impact of liver fat on diastolic autonomic dysfunction. Cardiovascular disease is the principle cause of death in patients with elevated liver fat unrelated to alcohol consumption, more so than liver-related morbidity and mortality. The aim of this study was to evaluate the relationship between liver fat and cardiac and autonomic function, as well as to assess how impairment in cardiac and autonomic function is influenced by metabolic risk factors. Cardiovascular and autonomic function were assessed in 96 sedentary individuals: i) non-alcoholic fatty liver disease (NAFLD) (n = 46, hepatic steatosis >5% by magnetic resonance spectroscopy), ii) Hepatic steatosis and alcohol (dual aetiology fatty liver disease [DAFLD]) (n = 16, hepatic steatosis >5%, consuming >20 g/day of alcohol) and iii) CONTROL (n = 34, no cardiac, liver or metabolic disorders,
ISSN:0168-8278
1600-0641
DOI:10.1016/j.jhep.2019.01.035